Avita Medical (ASX:AVH) has announced the US FDA has issued a premarket approval for its RECELL GO skin cell harvesting device.
The system allows patients requiring burns and wound treatment to see improved healing outcomes with less donor skin needed, and reportedly less pain.
In patients where burns were less than 50% of total body surface area, the system also led to less time in hospital beds, according to Avita.
The NASDAQ-dual-lister described RECELL GO as enhancing Spray-On Skin Cells (a registered product) with the potential to reduce burden on medical staff in emergency rooms and care wards.
The company also reports it has made it easier for medical staff to work with enzymes upon which the product relies.
The product will be launched in burn treatment centres in June.
“FDA approval of RECELL GO marks a shift in the treatment of partial-thickness and full- thickness wounds,” Avita CEO Jim Corbett said.
“We believe that this transformative shift will empower more clinicians to achieve optimal outcomes for their patients.”
AVH last traded at $2.66/sh.